Elliott M A, Dewald G W, Tefferi A, Hanson C A
Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Leukemia. 2001 Jan;15(1):35-40. doi: 10.1038/sj.leu.2401993.
This report describes a single institution's recent experience with six patients fulfilling the diagnostic criteria of chronic neutrophilic leukemia. No patient had the Philadelphia chromosome or the BCR/ABL fusion gene. None of the common cytogenetic abnormalities characteristic of myeloid disorders were detected. Two patients demonstrated clonal evolution during the course of the disease. All responded initially to therapy with hydroxyurea with control of leukocytosis and reduction in splenomegaly. Three patients eventually became refractory to hydroxyurea, manifesting progressive neutrophilia without blastic transformation. Aggressive chemotherapy to control progressive leukocytosis resulted in death due to cytopenias in two of these patients. The third patient received less intensive chemotherapy and died of progressive disease. One patient died after transformation of the disease into undifferentiated acute myeloid leukemia. Two patients remain alive with stable disease on hydroxyurea therapy, 12 and 54 months after initial diagnosis. Chronic neutrophilic leukemia is a rare clinicopathologic entity that can be distinguished from chronic myelogenous leukemia, the recently described neutrophilic-chronic myelogenous leukemia, and myelodysplastic syndrome. The clinical course is heterogeneous, with a definite risk of death from either blastic transformation or progressive neutrophilic leukocytosis. Continued study and reporting of these cases must be encouraged.
本报告描述了一家机构近期对6例符合慢性中性粒细胞白血病诊断标准患者的诊治经验。所有患者均无费城染色体或BCR/ABL融合基因。未检测到髓系疾病常见的细胞遗传学异常。2例患者在病程中出现克隆演变。所有患者最初对羟基脲治疗均有反应,白细胞增多得到控制,脾肿大减轻。3例患者最终对羟基脲耐药,表现为进行性中性粒细胞增多但无原始细胞转化。为控制进行性白细胞增多而进行的积极化疗导致其中2例患者因血细胞减少死亡。第3例患者接受的化疗强度较低,死于疾病进展。1例患者在疾病转化为未分化急性髓系白血病后死亡。2例患者在初始诊断后12个月和54个月,接受羟基脲治疗病情稳定,仍存活。慢性中性粒细胞白血病是一种罕见的临床病理实体,可与慢性粒细胞白血病、最近描述的中性粒细胞型慢性粒细胞白血病和骨髓增生异常综合征相鉴别。临床病程各异,存在因原始细胞转化或进行性中性粒细胞增多而死亡的明确风险。必须鼓励对这些病例进行持续研究和报告。